[go: up one dir, main page]

MEP5608A - Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli - Google Patents

Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli

Info

Publication number
MEP5608A
MEP5608A MEP-56/08A MEP5608A MEP5608A ME P5608 A MEP5608 A ME P5608A ME P5608 A MEP5608 A ME P5608A ME P5608 A MEP5608 A ME P5608A
Authority
ME
Montenegro
Prior art keywords
fluorophenyl
chromane
physiologically acceptable
methylaminomethyl
pyridyl
Prior art date
Application number
MEP-56/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Gerd Bartoszyk
Hermann Russ
Christoph Seyfried
Frank Weber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MEP5608A publication Critical patent/MEP5608A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-56/08A 2000-03-10 2001-02-01 Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli MEP5608A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00104531 2000-03-10
PCT/EP2001/001038 WO2001068063A2 (en) 2000-03-10 2001-02-01 Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

Publications (1)

Publication Number Publication Date
MEP5608A true MEP5608A (xx) 2010-02-10

Family

ID=8168017

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-56/08A MEP5608A (xx) 2000-03-10 2001-02-01 Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli

Country Status (29)

Country Link
US (1) US7928128B2 (xx)
EP (2) EP1645273A3 (xx)
JP (1) JP4901046B2 (xx)
KR (1) KR100830139B1 (xx)
CN (1) CN1188123C (xx)
AR (1) AR033807A1 (xx)
AT (1) ATE307578T1 (xx)
AU (2) AU3022201A (xx)
BR (1) BR0109119A (xx)
CA (1) CA2402402C (xx)
CO (1) CO5271686A1 (xx)
CZ (1) CZ301807B6 (xx)
DE (1) DE60114419T2 (xx)
DK (1) DK1299099T3 (xx)
ES (1) ES2251460T3 (xx)
HK (1) HK1054198B (xx)
HU (1) HU229309B1 (xx)
ME (1) MEP5608A (xx)
MX (1) MXPA02008800A (xx)
MY (1) MY136976A (xx)
NO (1) NO329583B1 (xx)
PL (1) PL200781B1 (xx)
RS (1) RS51316B (xx)
RU (1) RU2278663C2 (xx)
SI (1) SI1299099T1 (xx)
SK (1) SK286933B6 (xx)
UA (1) UA73981C2 (xx)
WO (1) WO2001068063A2 (xx)
ZA (1) ZA200208133B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
CN1292749C (zh) * 2001-07-26 2007-01-03 默克专利股份有限公司 2－[5－(4－氟苯基)－3－吡啶基甲氨基甲基]苯并二氢吡喃及其生理学上可接受的盐的新用途
US7618988B2 (en) * 2001-09-19 2009-11-17 Merck Patentgesellschaft Use of substituted aminomethyl chromans
AU2006261314B2 (en) * 2005-06-21 2012-03-22 Merck Patent Gmbh Solid pharmaceutical preparation containing (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
CN108937972A (zh) * 2018-06-08 2018-12-07 青岛大学附属医院 一种多特征融合的就诊用户情绪监控方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
ATE145208T1 (de) 1990-07-06 1996-11-15 Yoshitomi Pharmaceutical Kondensierte thiophenverbindungen und deren verwendung
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
EP0630238A4 (en) 1992-03-11 1995-05-24 Interneuron Pharma REDUCTION OF FLUCTUATIONS AFTER MEALS OF PLASMIC CONCENTRATIONS OF LARGE NEUTRAL ACIDS.
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
JPH08503448A (ja) * 1992-12-07 1996-04-16 メレルダウファーマス−ティカルズ インコーポレイテッド ５ｈｔ▲下１▼▲ａ▼受容体アゴニストによる不随意運動の処置
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
CA2177046A1 (en) * 1993-11-19 1995-05-26 Mark Froimowitz Octahydrobenzo[f]quinoline-based receptor agonists and antagonists
ATE183184T1 (de) * 1994-01-31 1999-08-15 Pfizer Neuroprotektive chroman verbindungen
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
SI0707007T1 (en) * 1994-10-14 2002-04-30 Merck Patent Gmbh (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)chromane as CNS active agent
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) * 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
EP0839144B1 (en) 1995-07-13 2001-09-19 Knoll GmbH Piperazine derivatives as therapeutic agents
US5670667A (en) 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) * 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
WO1999045906A1 (en) 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
JP3665567B2 (ja) * 1998-03-17 2005-06-29 ファイザー・プロダクツ・インク ビシクロ［２．２．１］ヘプタンおよび関連化合物
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
EP1299099B1 (en) 2005-10-26
PL356428A1 (en) 2004-06-28
ATE307578T1 (de) 2005-11-15
AU2001230222C1 (en) 2005-09-22
KR20030016236A (ko) 2003-02-26
HK1054198A1 (en) 2003-11-21
JP2004522692A (ja) 2004-07-29
EP1645273A3 (en) 2006-04-19
UA73981C2 (en) 2005-10-17
CO5271686A1 (es) 2003-04-30
AR033807A1 (es) 2004-01-07
CZ20022951A3 (cs) 2003-01-15
US20030181486A1 (en) 2003-09-25
CZ301807B6 (cs) 2010-06-30
EP1299099A2 (en) 2003-04-09
DE60114419D1 (de) 2005-12-01
DE60114419T2 (de) 2006-07-27
ES2251460T3 (es) 2006-05-01
US7928128B2 (en) 2011-04-19
SI1299099T1 (sl) 2006-04-30
MY136976A (en) 2008-12-31
WO2001068063A3 (en) 2002-05-10
KR100830139B1 (ko) 2008-05-20
RS51316B (sr) 2010-12-31
MXPA02008800A (es) 2003-02-12
RU2002127006A (ru) 2004-03-27
HUP0300079A2 (en) 2003-05-28
AU3022201A (en) 2001-09-24
SK286933B6 (sk) 2009-07-06
JP4901046B2 (ja) 2012-03-21
NO329583B1 (no) 2010-11-15
RU2278663C2 (ru) 2006-06-27
AU2001230222B2 (en) 2005-03-17
CN1188123C (zh) 2005-02-09
EP1645273A2 (en) 2006-04-12
DK1299099T3 (da) 2006-03-06
WO2001068063A2 (en) 2001-09-20
CN1416344A (zh) 2003-05-07
CA2402402C (en) 2013-01-22
HK1054198B (zh) 2005-05-20
HU229309B1 (en) 2013-10-28
PL200781B1 (pl) 2009-02-27
CA2402402A1 (en) 2001-09-20
ZA200208133B (en) 2004-04-01
YU67402A (sh) 2006-01-16
NO20024291D0 (no) 2002-09-09
NO20024291L (no) 2002-09-09
BR0109119A (pt) 2003-06-03
SK12642002A3 (sk) 2003-02-04

Similar Documents

Publication Publication Date Title
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
GEP20074047B (en) Pramipexole once-daily dosage form
GB0005251D0 (en) Therapeutic compounds
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
AU6473601A (en) Gabapentin analogues for sleep disorders
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CY1107616T1 (el) Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
MEP5608A (xx) Nova upotreba (r) – (-)-2-[5-(4-fluorofenil)-3-piridil- metilaminometil] - hromana i njegovih fiziološko prihvatljivi h soli
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
MY137595A (en) N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide for the treatment of cancer
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
HUP0402654A2 (hu) 2-[(2'-Halogén-3',5'-dialkoxi-fenil)-imino]-imidazolidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
GB0112494D0 (en) New therapeutic use
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
FR2802101B1 (fr) Association de cymemazine et d'un neuroleptique atypique
NO20010984D0 (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4- fluorfenyl)etyl]-4-piperidinmetanol for behandling av søvnforstyrrelser
FR2804867B1 (fr) Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose